Autoimmunity

Autoimmunity is the study of how the immune system can turn against the body it belongs to.

12 frameworks, from 1899 to today · Immunology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Autoimmunity is the study of how the immune system can turn against the body it belongs to. Its central puzzle is a paradox: the same machinery that recognizes and destroys invading microbes can, under some circumstances, recognize and destroy a person's own tissues1. What is at stake is not only a set of diseases—type 1 diabetes, rheumatoid arthritis, multiple sclerosis, lupus, and many others—but a fundamental question about how the immune system distinguishes self from non-self1. The history of autoimmunity is the history of how immunologists came to accept that such self-attack is real, how they explained it, and how they learned to measure and treat it.

Horror Autotoxicus and the Denial of Self-Attack

In the late nineteenth and early twentieth centuries, immunology was dominated by the study of humoral immunity—the protective action of antibodies in blood serum. The German bacteriologist Paul Ehrlich, working in the 1890s and early 1900s, proposed that the body possesses a natural aversion to attacking its own tissues. He called this principle horror autotoxicus—literally "fear of self-poisoning."12 Ehrlich reasoned that if antibodies could be raised against the body's own cells, the result would be catastrophic, and he believed the organism had evolved mechanisms to prevent it. This idea became a foundational assumption: the immune system was understood as a defense against foreign invaders, and self-tolerance was assumed to be absolute1.

The first serious challenge came from the work of the Russian-born immunologist Élie Metchnikoff, who had discovered phagocytosis in the 1880s, and from later clinicians who observed that animals injected with their own tissues could sometimes produce antibodies against them. In 1904, the French immunologist Jules Bordet and his colleague Octave Gengou demonstrated that antibodies could be raised against red blood cells of another species, and similar experiments with self-tissues followed. But these findings were often dismissed as laboratory artifacts or as consequences of tissue damage rather than genuine autoimmune reactions. The horror autotoxicus framework held sway because it fit the dominant view of immunity as a purely defensive, outward-facing system1.

Autoantibody Diagnostics and the Recognition of Autoimmune Disease

The decisive break came from clinical observation. In 1904, the German physician Julius Donath and the Austrian immunologist Karl Landsteiner described paroxysmal cold hemoglobinuria, a condition in which exposure to cold caused red blood cells to burst. They showed that a factor in the patient's serum—an antibody—bound to the patient's own red cells in the cold and triggered their destruction. This was one of the first clear demonstrations that an antibody could target self-tissue and cause disease.

A more systematic recognition followed in the 1940s and 1950s. In 1945, the American hematologist Robert Coombs and his colleagues developed the antiglobulin test (now called the Coombs test), which detected antibodies bound to red blood cells. This made it possible to diagnose autoimmune hemolytic anemia—a condition in which the body destroys its own red blood cells. Around the same time, the American physician Philip Hench and the biochemist Edward Kendall at the Mayo Clinic observed that cortisone, a steroid hormone, dramatically suppressed inflammation in rheumatoid arthritis. This suggested that the immune system was actively involved in the disease, though the precise mechanism remained unclear.

The 1950s brought a wave of autoantibody discoveries. In 1957, the British immunologist Deborah Doniach and her colleagues described antibodies against thyroid tissue in patients with Hashimoto's thyroiditis, a chronic inflammatory disease of the thyroid gland. In the same period, antibodies against cell nuclei (antinuclear antibodies) were found in patients with systemic lupus erythematosus (SLE), a disease in which the immune system attacks multiple organs. These findings established that autoantibodies were not rare curiosities but common features of a class of diseases. The term "autoimmune disease" entered clinical use, and the horror autotoxicus doctrine was effectively overturned—though the question of how self-tolerance normally works remained open.

Acquired Immunological Tolerance and the Clonal Selection Theory

The theoretical foundation for understanding self-tolerance came from two related developments in the mid-twentieth century. The first was the demonstration of acquired immunological tolerance. In 1953, the British immunologist Peter Medawar and his colleagues showed that mice injected with foreign cells before birth or shortly after birth would accept skin grafts from the same donor strain later in life. This phenomenon, called neonatal tolerance, proved that the immune system could be taught to accept foreign tissue if exposed to it early enough. Medawar's work, building on earlier observations by the Australian immunologist Frank Macfarlane Burnet, suggested that tolerance is not innate but acquired through exposure during development.

The second development was the clonal selection theory, proposed by Burnet in 19573. Burnet argued that each lymphocyte (a type of white blood cell) carries a unique receptor for a specific antigen, and that when an antigen binds to that receptor, the lymphocyte is selected to proliferate and produce antibodies or effector cells3. Crucially, Burnet proposed that lymphocytes with receptors that recognize self-antigens are eliminated during development—a process he called "clonal deletion."14 This provided a mechanism for self-tolerance: the immune system learns to ignore self by destroying self-reactive clones before they can mature1. The clonal selection theory became the central framework of modern immunology and offered a clear explanation for why autoimmunity is the exception rather than the rule.

The MHC-HLA Genetic Association Framework

While Burnet's theory explained how self-tolerance might be established, it did not explain why some people develop autoimmune diseases and others do not. The answer began to emerge from genetics. In the 1960s and 1970s, immunologists discovered the major histocompatibility complex (MHC)—a cluster of genes that encode proteins on the surface of cells that present antigens to T cells. In humans, this is called the human leukocyte antigen (HLA) system5. The MHC proteins are highly variable between individuals, and this variability determines which antigens are presented to the immune system6.

In 1973, the British immunologist John Dausset and the American immunologist Baruj Benacerraf, along with the Swiss immunologist Jean Dausset (working independently), showed that certain HLA types were strongly associated with specific autoimmune diseases. For example, HLA-B27 was found to be linked to ankylosing spondylitis, a chronic inflammatory arthritis of the spine1. Later work in the 1980s and 1990s identified HLA-DR4 and HLA-DR3 associations with rheumatoid arthritis and type 1 diabetes, respectively. The MHC-HLA framework provided a genetic explanation for susceptibility: certain HLA molecules may present self-antigens in a way that activates self-reactive T cells, or may fail to present them in a way that induces tolerance. This framework remains central to understanding the genetic basis of autoimmunity.

Regulatory T Cells and the Active Suppression of Self-Reactivity

The clonal selection theory implied that self-reactive lymphocytes are deleted during development1. But in the 1980s and 1990s, immunologists discovered that self-reactive T cells are not always eliminated; some persist in the periphery and must be actively controlled. The key discovery was the regulatory T cell (Treg), a subset of T cells that suppresses the activity of other immune cells7. In 1995, the Japanese immunologist Shimon Sakaguchi and his colleagues showed that a specific subset of T cells—those expressing the marker CD25—could prevent autoimmune disease in mice. When these cells were removed, the mice developed spontaneous autoimmune conditions. This demonstrated that self-tolerance is not merely a passive process of deletion but an active one of suppression1.

The regulatory T cell theory was further solidified by the discovery of the transcription factor Foxp3, which is required for Treg development and function8. Mutations in the Foxp3 gene were found to cause a severe autoimmune syndrome in humans called IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked). This provided a direct link between Treg dysfunction and autoimmunity. The Treg framework shifted the understanding of autoimmunity from a simple failure of deletion to a more complex failure of active regulation.

The Hygiene and Old Friends Hypotheses

Why do autoimmune diseases appear more common in wealthy, urbanized societies? In 1989, the British epidemiologist David Strachan proposed the hygiene hypothesis, suggesting that reduced exposure to infections in early childhood—due to improved sanitation and smaller family sizes—leads to a higher risk of allergic and autoimmune diseases. The idea was that the immune system needs to be "educated" by microbes to develop proper regulation.

This hypothesis was later refined into the "old friends" hypothesis by the British immunologist Graham Rook in the 2000s. Rook argued that it is not infections per se that matter, but exposure to harmless environmental microbes—particularly those that co-evolved with humans, such as certain bacteria and helminths (parasitic worms). These "old friends" help train the immune system to tolerate self and harmless antigens. The hygiene and old friends hypotheses provided an ecological and evolutionary perspective on autoimmunity, linking changes in human lifestyle to the rise in autoimmune diseases. They also motivated research into the microbiome—the community of microbes living in and on the body—as a regulator of immune tolerance.

The Microbiome-Immune Regulation Framework

The microbiome emerged as a major focus in the 2000s and 2010s, driven by advances in DNA sequencing that allowed researchers to catalog the bacteria, viruses, and fungi living in the gut, skin, and other sites. Studies in mice showed that germ-free animals—raised in sterile conditions—have altered immune development and are more susceptible to autoimmune conditions. In humans, changes in the gut microbiome were associated with diseases such as inflammatory bowel disease, type 1 diabetes, and multiple sclerosis.

The microbiome-immune regulation framework proposes that the composition of the microbiota influences the balance between pro-inflammatory and regulatory immune responses. For example, certain gut bacteria produce short-chain fatty acids that promote Treg development, while others may trigger inflammatory pathways. This framework connects the hygiene hypothesis to molecular mechanisms and has opened new avenues for therapy, such as fecal microbiota transplantation and probiotic interventions, though clinical evidence for their efficacy in autoimmunity remains limited.

The Immune Checkpoint Framework and Cytokine Targeting

The late twentieth and early twenty-first centuries saw the rise of targeted therapies that manipulate specific immune pathways. The immune checkpoint framework emerged from the discovery of molecules that either activate or inhibit T cells. In the 1990s, the American immunologist James Allison and the Japanese immunologist Tasuku Honjo independently identified CTLA-4 and PD-1, respectively, as inhibitory receptors on T cells. Blocking these checkpoints—using antibodies such as ipilimumab (anti-CTLA-4) and pembrolizumab (anti-PD-1)—releases the brakes on the immune system and has proven remarkably effective against some cancers. But this same strategy can trigger autoimmune side effects, demonstrating that checkpoints are critical for maintaining self-tolerance.

Conversely, the cytokine and biologic pathway targeting framework focuses on blocking specific inflammatory molecules. Tumor necrosis factor (TNF) was identified in the 1970s and 1980s as a key mediator of inflammation. In the late 1990s, anti-TNF therapies (such as infliximab and etanercept) were approved for rheumatoid arthritis and Crohn's disease, revolutionizing treatment. Later, therapies targeting interleukins (such as IL-6 and IL-17) and B cells (such as rituximab, which depletes B cells) were developed. These biologics demonstrated that autoimmunity could be treated by interrupting specific molecular pathways, and they provided proof that autoantibodies and inflammatory cytokines are directly pathogenic in many diseases.

Antigen-Specific Tolerance Induction

While broad immunosuppression and cytokine blockade are effective, they carry risks of infection and cancer. A long-standing goal has been antigen-specific tolerance induction—teaching the immune system to tolerate a specific self-antigen without suppressing the rest of the immune response. Early attempts in the 1970s and 1980s used oral administration of antigens (oral tolerance) to suppress autoimmune responses in animal models. For example, feeding mice with myelin basic protein—a component of the nerve sheath—could prevent experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.

More recent approaches include the use of nanoparticles coated with antigens to induce Tregs, and the engineering of tolerogenic dendritic cells. While these strategies have shown promise in animal models, translating them to human autoimmune diseases has proven difficult. Clinical trials of oral tolerance in multiple sclerosis and rheumatoid arthritis have had mixed results, and antigen-specific tolerance remains an active area of research rather than a standard therapy.

Molecular Subtyping and Heterogeneity

As the understanding of autoimmunity deepened, it became clear that diseases like lupus or rheumatoid arthritis are not single entities but collections of subtypes with different molecular mechanisms. The molecular subtyping and heterogeneity framework emerged from genomics and transcriptomics in the 2000s and 2010s. Researchers began to classify patients based on gene expression profiles, autoantibody patterns, and cytokine signatures. For example, in lupus, some patients have high levels of type I interferon—a class of antiviral proteins—while others do not. This heterogeneity explains why some patients respond to certain therapies and others do not.

Molecular subtyping has led to the concept of precision medicine in autoimmunity: tailoring treatment to the specific molecular pathway driving a patient's disease. It has also revealed that autoimmune diseases share some mechanisms with immunodeficiency and cancer, blurring the boundaries between disease categories.

The Present: Integrated Approaches and Open Questions

Today, autoimmunity research integrates genetics, immunology, microbiology, and clinical medicine. The main approaches in use descend directly from the history above: clonal selection and tolerance theory provide the conceptual foundation; MHC-HLA typing and autoantibody diagnostics are standard clinical tools; regulatory T cell biology informs new therapies; the microbiome is a target for intervention; and biologic drugs targeting cytokines and checkpoints are mainstays of treatment. Antigen-specific tolerance and molecular subtyping represent the frontier, aiming for therapies that are both precise and durable.

Open questions remain. Why does self-tolerance fail in some people and not others? How do environmental factors—infections, diet, stress—interact with genetic susceptibility? Can we induce lasting tolerance without compromising defense against infection? And how can the heterogeneity of autoimmune diseases be harnessed to deliver the right treatment to the right patient? These questions continue to drive the field, which has come a long way from the doctrine of horror autotoxicus but still faces the fundamental puzzle of how the immune system decides whom to attack.

References

  1. Autoimmunity (introduction, History, Immunological tolerance, Genetic factors), Wikipedia
  2. Paul Ehrlich (First work on immunity), Wikipedia
  3. Clonal selection, Wikipedia
  4. Immune tolerance (Historical background), Wikipedia
  5. Human leukocyte antigen, Wikipedia
  6. Major histocompatibility complex, Wikipedia
  7. Regulatory T cell, Wikipedia
  8. FOXP3, Wikipedia

The frameworks of Autoimmunity

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1899-1955

    Horror Autotoxicus

    Does the body ever attack its own tissues?

    Fly to its tower in Nousfarer

  2. 1904-Present
  3. 1953-1985

    Immune tolerance

    How does the immune system learn to accept self?

    Fly to its tower in Nousfarer

  4. 1957-Present

    Clonal selection

    How does the immune system choose which cells to expand?

    Fly to its tower in Nousfarer

  5. 1970-Present

    Antigen-Specific Tolerance Induction

    Can tolerance to a specific antigen be induced?

    Fly to its tower in Nousfarer

  6. 1973-Present

    Human leukocyte antigen

    Why do some people get autoimmune disease and others not?

    Fly to its tower in Nousfarer

  7. 1989-Present

    Hygiene and Old Friends Hypotheses

    Why are autoimmune diseases more common in rich societies?

    Fly to its tower in Nousfarer

  8. 1995-Present

    Immune checkpoint

    How are immune responses held in check?

    Fly to its tower in Nousfarer

  9. 1995-Present

    Regulatory T cell

    Which cells actively suppress immune attack on self?

    Fly to its tower in Nousfarer

  10. 1998-Present

    Cytokine and Biologic Pathway Targeting

    Which immune signaling molecules drive autoimmune damage?

    Fly to its tower in Nousfarer

  11. 2005-Present
  12. 2005-Present

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Horror AutotoxicusAutoantibody-Based Autoimmune Disease…Immune toleranceClonal selectionAntigen-Specific Tolerance InductionHuman leukocyte antigenHygiene and Old Friends HypothesesImmune checkpointRegulatory T cellCytokine and Biologic Pathway Targeti…Microbiome-Immune Regulation FrameworkMolecular Subtyping and Precision Med…

Beyond the field

Where Autoimmunity's ideas came from in other fields, and what they led to there: the strongest 12 of 86 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Autoimmunity is a planet in Nousfarer

Its city has a tower for each of these 12 frameworks. Land, walk in, and climb one concept at a time.

Land on Autoimmunity

Related fields

Fields its ideas are linked to

More in Immunology

See where Autoimmunity sits on the Map of Human Knowledge